Fengyan Xu
-
- Immune Cell Function and Interaction 5
- T-cell and B-cell Immunology 4
- Immunotherapy and Immune Responses 3
-
- Cancer Immunotherapy and Biomarkers 8
-
- Ophthalmology and Eye Disorders 2
-
- Antibiotics Pharmacokinetics and Efficacy 6
-
- Pneumonia and Respiratory Infections 3
-
- Receptor Mechanisms and Signaling 2
- Cited by
- ImmunologyOncologyCancer Research
- Journals
- PLoS ONE (4 papers)Journal of Affective Disorders (1 paper)Clinical Pharmacokinetics (2 papers)
- Partner nations
- ChinaUnited States
In The Last Decade
Fengyan Xu
29 papers receiving 356 citations
Peers
Comparison fields: 5 of 66
- Immunology 163
- Oncology 158
- Cancer Research 43
- Virology 11
- Pathology and Forensic Medicine 40
Countries citing papers authored by Fengyan Xu
This map shows the geographic impact of Fengyan Xu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Fengyan Xu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Fengyan Xu more than expected).
Fields of papers citing papers by Fengyan Xu
This network shows the impact of papers produced by Fengyan Xu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Fengyan Xu. The network helps show where Fengyan Xu may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Fengyan Xu, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 0 | |
| 2 | 2024 | 4 | |
| 3 | 2024 | 3 | |
| 4 | 2024 | 3 | |
| 5 | 2023 | 2 | |
| 6 | 2023 | 0 | |
| 7 | 2023 | 1 | |
| 8 | 2021 | 13 | |
| 9 | 2021 | 18 | |
| 10 | 2021 | 3 | |
| 11 | 2020 | 1 | |
| 12 | 2019 | 5 | |
| 13 | 2018 | 6 | |
| 14 | 2016 | 5 | |
| 15 | 2014 | 31 | |
| 16 | 2012 | 11 | |
| 17 | 2012 | 32 | |
| 18 | 2011 | 17 | |
| 19 | 2010 | 7 | |
| 20 | 2009 | 40 |
About Fengyan Xu
Fengyan Xu is a scholar working on Oncology, Immunology and Pharmacology, having authored 31 papers that have together received 361 indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (8 papers), Antibiotics Pharmacokinetics and Efficacy (6 papers), Immune Cell Function and Interaction (5 papers), T-cell and B-cell Immunology (4 papers), Immunotherapy and Immune Responses (3 papers), Pneumonia and Respiratory Infections (3 papers), Ophthalmology and Eye Disorders (2 papers) and Receptor Mechanisms and Signaling (2 papers). The work is most often cited by research in Immunology (163 citations), Oncology (158 citations) and Cancer Research (43 citations). Fengyan Xu has collaborated with scholars based in China and United States. Frequent co-authors include Zhenkun Fu, Da Pang, Dianjun Li, Dalin Li, Weiguang Yuan, Shuang Chen, Qiujin Zhang, Xiang Gao, Hua Zhang and Jie Guan. Their work appears in journals such as PLoS ONE, Journal of Affective Disorders and Clinical Pharmacokinetics.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.